CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
278.55MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4320xvs all stocks
52-Week Change
315.18%vs all stocks
Market Capitalization
278.55MUSDvs all stocks (USD)
Enterprise Value
145.89MUSDvs all stocks (USD)
Forward P/E
-3.85xvs Biotechnology peers
Price to Book (MRQ)
1.84xvs Biotechnology peers
Enterprise to EBITDA
-1.67xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-36.76%vs Biotechnology peers
Return on Equity (TTM)
-74.17%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 17, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-87.35MUSDvs all stocks (USD)
Net Income (TTM)
-88.87MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-78.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-47.77MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-100.85MUSDvs all stocks (USD)
Pre-tax Income
-101.69MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-101.69MUSDFY2025 · Dec 31, 2025EBIT
-100.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-96.21MUSDFY2025 · Dec 31, 2025Research & Development
77.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.60MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-101.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-88.73MUSDFY2025 · Dec 31, 2025Free Cash Flow
-88.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
16.44MUSDFY2025 · Dec 31, 2025Interest Paid
1.26MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-101.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
706.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.58MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
272.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-212.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-51.59MUSDFY2025 · Dec 31, 2025Sale of Investments
134.39MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
82.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.36MUSDFY2025 · Dec 31, 2025Other Financing Charges
1.69MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
324.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
134.54MSharesUpdated Jul 17, 2026Float Shares
64.43MSharesUpdated Jul 17, 2026Shares Short
6.32MSharesUpdated Jul 17, 2026Short Ratio
3.18daysvs all stocks
Short % of Shares Outstanding
5.22%vs all stocks
% Held by Insiders
0.92%vs all stocks
% Held by Institutions
78.79%vs all stocks
Total Cash (MRQ)
140.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.04USDUpdated Jul 17, 2026Total Debt (MRQ)
13.05MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0862xvs Biotechnology peers
Current Ratio (MRQ)
7.21xvs Biotechnology peers
Book Value per Share (MRQ)
1.13USDUpdated Jul 17, 2026Total Assets
59.05MUSDvs all stocks (USD)
Total Current Assets
50.73MUSDFY2025 · Dec 31, 2025Total Liabilities
33.06MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.51MUSDFY2025 · Dec 31, 2025Total Current Liabilities
24.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
16.37MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.42MUSDFY2025 · Dec 31, 2025Accounts Payable
4.91MUSDFY2025 · Dec 31, 2025Short-term Debt
5.22MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.32MUSDFY2025 · Dec 31, 2025Long-term Debt
4.53MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.98MUSDFY2025 · Dec 31, 2025Common Stock (Book)
54.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-722.82MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
25.98MUSDvs all stocks (USD)
52-Week Low
0.4440USDUpdated Jul 17, 202652-Week High
2.66USDUpdated Jul 17, 202652-Week Change
315.18%vs all stocks
Beta
0.4320xvs all stocks
50-Day MA
1.88USDUpdated Jul 17, 2026200-Day MA
1.75USDUpdated Jul 17, 2026Avg 10-Day Volume
1.10MSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.74MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-1.49USDUpdated Jul 17, 2026Other Income / Expense
-3.21MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Hile Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule